New drug combo aims to boost immune system against Hard-to-Treat cancers

NCT ID NCT04215978

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now complete, and results will help guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-A445 (gimistotug) and tislelizumab
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma nasopharyngeal carcinoma neoplasm non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) NASOPHARYNGEAL CARCINOMA (NPC) NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Affiliated Zhongshan Hospital Of Fudan University

Shanghai, Shanghai Municipality, 200032, China
Auckland City Hospital

Auckland, 1023, New Zealand
Blacktown Cancer And Haematology Centre

Blacktown, New South Wales, 2148, Australia
California Cancer Associates for Research & Excellence (cCARE)

San Diego, California, 92127, United States
Cha Bundang Medical Center, Cha University

Gyeonggido, Gyeonggi-do, 13496, South Korea
Changhua Christian Hospital

Changhua, NAP, 500-06, Taiwan
Jinan Central Hospital

Jinan, Shandong, 250013, China
King Chulalongkorn Memorial Hospital (Chulalongkorn University)

Bangkok, 10330, Thailand
Linear Clinical Research

Nedlands, Western Australia, 6009, Australia
Linyi Cancer Hospital

Linyi, Shandong, 276001, China
Monash Health

Clayton, Victoria, 3168, Australia
National Cancer Center (NCC)

Goyang-si, Gyeonggi-do, 10408, South Korea
National Cheng Kung University Hospital

Tainan, 704, Taiwan
Nucleus Network

Melbourne, Victoria, 3004, Australia
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Pindara Private Hospital

Benowa, Queensland, 4217, Australia
Princess Alexandra Hospital

Brisbane, Queensland, 4102, Australia
Ramathibodi Hospital Mahidol University

Bangkok, 10400, Thailand
Sarawak General Hospital

Kuching, 93586, Malaysia
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggido, 13620, South Korea
Severance Hospital Yonsei University Health System

Seoul, Seoul Teugbyeolsi, 03722, South Korea
Sir Run Run Shaw Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China
Srinagarind Hospital (Khon Kaen University)

Muang, 40002, Thailand
The Catholic University of Korea, St. Vincent's Hospital

Suwon, Gyeonggi-do, 16247, South Korea
The Second Xiangya Hospital Of Central South University

Changsha, Hunan, 410011, China
UPMC Hillman Cancer Center (Univ Of Pittsburgh)

Pittsburgh, Pennsylvania, 15232, United States
Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology

Wuhan, Hubei, 430022, China
University of Malaya Medical Centre

Kuala Lumpur, 50603, Malaysia
Valkyrie Clinical Trials

Los Angeles, California, 90067, United States
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.